Last reviewed · How we verify

Malignant tumor of thyroid gland — Treatment Landscape & Competitive Intelligence

Malignant tumor of thyroid gland (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malignant tumor of thyroid gland, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Synthroid levothyroxine Generic (originally multiple — AbbVie/Synthroid) Thyroid hormone THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial 2002-08-13
Unithroid LEVOTHYROXINE SODIUM Fresenius Kabi l-Thyroxine Thyroid hormone receptor beta 2000-01-01
Doxorubicin Hydrochloride doxorubicin Pfizer Anthracycline Topoisomerase Inhibitor Aurora kinase A 1974-01-01
Liposomal Doxorubicin liposomal-doxorubicin Pfizer doxorubicin 72 kDa type IV collagenase 1974-01-01
Triostat LIOTHYRONINE Pfizer l-Triiodothyronine Thyroid hormone receptor alpha 1956-01-01
Adriamycin Adriamycin Johann Wolfgang Goethe University Hospital Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
levothyroxin levothyroxin Ain Shams University THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial
Thyroxine Thyroxine Cancer Institute and Hospital, Chinese Academy of Medical Sciences THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial
Triiodothyronine Triiodothyronine Northwell Health THAP domain-containing protein 1, Cytochrome P450 2C9, Proliferating cell nuclear antigen
Hydroxydaunomycin Hydroxydaunomycin Weill Medical College of Cornell University Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 3 drugs in Malignant tumor of thyroid gland
  2. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in Malignant tumor of thyroid gland
  3. Chipscreen Biosciences, Ltd. · 1 drug in Malignant tumor of thyroid gland
  4. Fresenius Kabi · 1 drug in Malignant tumor of thyroid gland
  5. Generic (originally multiple — AbbVie/Synthroid) · 1 drug in Malignant tumor of thyroid gland
  6. Johann Wolfgang Goethe University Hospital · 1 drug in Malignant tumor of thyroid gland
  7. Northwell Health · 1 drug in Malignant tumor of thyroid gland
  8. University of Colorado, Denver · 1 drug in Malignant tumor of thyroid gland
  9. Ain Shams University · 1 drug in Malignant tumor of thyroid gland
  10. Weill Medical College of Cornell University · 1 drug in Malignant tumor of thyroid gland

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malignant tumor of thyroid gland:

Cite this brief

Drug Landscape (2026). Malignant tumor of thyroid gland — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-tumor-of-thyroid-gland. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing